Caris Life Sciences, Inc.
CAI Nasdaq
SEC CIK 2019410
Follow Caris Life Sciences
Weekly email: filings, results
Revenue, last quarter
$275.4M
+27% vs same quarter last year
Net income
$15.3M
−37.3% vs same quarter last year
EPS, diluted
$0.05
−37.5% vs same quarter last year
Operating cash flow
−$22.2M
−135.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $812M | −$68.1M |
| FY24 | $412.3M | −$281.9M |
| FY23 | $306.1M | −$341.4M |
| FY22 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 5.6% | −8.4% |
| FY24 | −62.4% | −68.4% |
| FY23 | −104.4% | −111.5% |
| FY22 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $66.9M |
| FY24 | −$253.6M |
| FY23 | −$298.4M |
| FY22 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $113K |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | - |
- Caris Life Sciences
- Healthcare median
Show the numbers
| Year | Caris Life Sciences | Healthcare median |
|---|---|---|
| FY25 | −8.4% | −30.6% |
| FY24 | −68.4% | −47% |
| FY23 | −111.5% | −58% |
| FY22 | - | −80.4% |